Advertisement

Topics

Companies Related to "Recurrent lower respiratory tract infections children" [Most Relevant Company Matches] RSS

11:55 EST 17th December 2018 | BioPortfolio

Here are the most relevant search results for "Recurrent lower respiratory tract infections children" found in our extensive corporate database of over 50,000 company records.

Showing "Recurrent lower respiratory tract infections children" Companies 1–25 of 1,800+

Relevant

Advanced Life Sciences Holdings, Inc.

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel oral once-a-day antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens inclu...


Advanced Discovries for Health

We are a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs in the areas of infectious disease, inflammation and oncology. Using our internal discovery capabilities and our network of pharmaceutical and academic partners, we have assembled a promising pipeline of clinical and preclinical product candidates for the treatment of respiratory tract inf...

Pulmatrix

Pulmatrix is discovering and developing a new class of therapies --inhaled cationic airway lining modulators (iCALM) –to prevent and treat respiratory infections and acute exacerbations of chronic respiratory diseases. iCALM therapies have broad potential to treat and prevent a wide range of respiratory diseases, including respiratory infections such ...


Pulmatrix, Inc.

Pulmatrix, Inc., is a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases. Pulmatrix’s lead proprietary therapies, called inhaled cationic airway lining modulators (iCALM™), are a novel approach to prevent and treat acute exacerbations an...

Allegro Diagnostics Corp.

Allegro Diagnostics’ molecular testing platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer and diseases of the airway. The “field of injury” principle on which the platform is based refers to the detectable molecular changes that occur throughout the respiratory tract in ...

Rebiotix Inc.

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for th...

Enanta Pharmaceuticals

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is developing novel protease, NS5A, polymerase, and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of m...

Virion Biotherapeutics

Virion Biotherapeutics seeks to transform the management of respiratory viral infections with the development of its proprietary Therapeutic Interfering Particles (TIPs). These first-in-class biologicals enhance a naturally-occurring dual mechanism that interferes with viral replication, preventing infection and stopping disease, enabling treatment of the ...

Adams Respiratory Therapeutics

We're a specialty pharmaceutical company focused on late-stage development, commercialization and marketing of over-the-counter (OTC) and prescription (Rx) pharmaceuticals for the treatment of respiratory disorders. We currently market ten products in the United States: Mucinex® SE, Mucinex® DM, Mucinex® D, Humibid® SE, two Delsym® products, and four products in our Children's Mucinex® line....

Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. is a leading developer of improved treatments for diseases that affect mucosal tissues. Using its proprietary mucus penetrating particle (MPP) technology platform, Kala is able to formulate active pharmaceutical ingredients so they are able to pass through human mucus secretions, in diverse organs, including the respiratory tract...

TRACT Therapeutics, Inc.

TRACT Therapeutics, Inc. is a clinical-stage biotechnology company developing a novel therapeutic approach to restoring immune balance in transplantation and autoimmune disease. It’s proprietary platform technology, using autologous, polyclonally expanded T-regulatory cells was developed at Northwestern University by pioneer, Joseph R Leventhal, MD, P...

Aradigm Corporation and Grifols S.A.

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. Aradigm has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and prevention of ...

IP&MA, Inc

Since 1996, IP&MA has been assisting health care organizations and related industries prevent infectious and other adverse events. IP&MA's professionals have successfully worked with clients to: Decrease the ventilator associated pneumonia rate in intensive care patients by 29%; providing a cost avoidance of over $160,000 per year. Lower the overall nosocomial infection rate for a long term acut...

Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic...

ENBREL

ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your d...

Children’s Healthcare of Atlanta

Children’s Healthcare of Atlanta enhances the lives of children through excellence in patient care, research and education. Serving our community with more than 30 pediatric specialties, Children's is committed to being a model for pediatric care.Children’s was formed in 1998 when Egleston Children's Health Care System and Scottish Rite Children's Medical Center joined to form a unified health...

Respiratory Therapeutics Group

RTG is a global manufacturer of Respiratory Devices, with an extensive brand portfolio of respiratory disposable devices, products and service solutions designed by Respiratory Therapists for a diverse range of therapies. RTG Products are distributed in Acute, Sub Acute, Skilled Nursing, Home and Hospice Settings, through our increasing network of d...

ViroPharma

At ViroPharma, we are dedicated to transforming the lives of patients through the commercialization of new and important medicines. Our goal is to focus on developing and marketing innovative products addressing unmet medical needs. We are continuing to position ourselves to do just that. We are a pharmaceutical company focused on the development and commercialization of important medicines to a...

Corus Pharma Inc

Corus Pharma seeks to develop drugs to treat unmet needs in the infectious diseases and respiratory areas. The company's core competencies reside in the identification of drug candidates, rapid clinical development and FDA approval of its products. Target development candidates will be identified through a combination of internal ideas, academic research and a search of projects in other organizat...

resTORbio, Inc.

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caus...

DEBRA

Epidermolysis Bullosa (EB) is a rare genetic disorder characterized by the presence of extremely fragile skin and recurrent blister formation, resulting from minor mechanical friction or trauma. Secondary complications can include infections, oral ulcerations, dental decay, esophageal blistering, corneal erosions, osteoporosis and psychological trauma. Thi...

Discovery Laboratories

Discovery Laboratories, Inc. is a specialty pharmaceutical company leveraging its platform technology in humanized lung surfactants to develop novel respiratory therapies and pulmonary drug delivery products. Surfactants are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen.Our humanized surfactant technology is being developed initially for critical care pa...

Entasis Therapeutics Holdings Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SU...

Adamed Sp. z o.o.

Our priority is production of ethical drugs. We are leaders on the market of new generation drugs in many therapeutic groups such as cardiology, psychiatry, pulmonology, gynecology and treatment of urinal tract infections.We invest in research that is set to find effective and innovative original drugs which can be used for the most common diseases of our time, diabetes, venous thromboembolism (VT...

NeoTract, Inc.

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent device designed to treat lower urinary tract symptoms (LUTS).


More From BioPortfolio on "Recurrent lower respiratory tract infections children"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks